A

Attovia Therapeutics

HealthSan Carlos, United States

Attovia Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation therapies for immune-mediated diseases. The company holds an exclusive global license to the ATTOBODY biologics platform, which enables the rapid generation of diverse candidate molecules. Attovia has already nominated three product candidates and aims to advance their clinical development with proceeds from their recent IPO.

$289M · IPOVisit website ↗

🏆 Featured in Datapile’s Q3 2026 USA Funding Report

Read the Q3 2026 USA report →
Add this badge to your site
Featured in Datapile’s Q3 2026 USA Funding Report
<a href="https://datapile.co/reports/q3-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q3 2026 USA Funding Report</a>

Funding history

  1. $289MIPO2026-08-06
    Source: news.google.com ↗

Investors in Attovia Therapeutics

Backers from this company's tracked funding rounds.

More Health companies

Recently funded startups in the same category.

Related on Datapile